Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.

MLA

Lancaster, Lisa, et al. “Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Integrated Analysis of Cumulative Data from 5 Clinical Trials.” BMJ Open Respiratory Research, vol. 3, no. 1, Jan. 2016, p. e000105. EBSCOhost, https://doi.org/10.1136/bmjresp-2015-000105.

APA

Lancaster, L., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., King, T. E., Jr, Lederer, D. J., Lin, Z., Nathan, S. D., Pereira, C. A., Swigris, J. J., Valeyre, D., & Noble, P. W. (2016). Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respiratory Research, 3(1), e000105. https://doi.org/10.1136/bmjresp-2015-000105

Chicago

Lancaster, Lisa, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, et al. 2016. “Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Integrated Analysis of Cumulative Data from 5 Clinical Trials.” BMJ Open Respiratory Research 3 (1): e000105. doi:10.1136/bmjresp-2015-000105.